黄斑变性
医学
纤维化
眼科
黄斑病
发病机制
病态的
吡非尼酮
脉络膜新生血管
病理
并发症
哌加他尼
病变
垂直波分
皮肤病科
重新调整用途
临床试验
生物信息学
炎症
作者
Heping Xu,Jiaxin Pu,Caijiao Yi,Wen Deng,Xiang‐Ling Yuan,Zhongping Chen,Qian Xiang,Qichang Wang,Feng Wen,Mei Chen
标识
DOI:10.1016/j.preteyeres.2026.101488
摘要
Macular subretinal fibrosis represents the end-stage complication of neovascular age-related macular degeneration (nAMD). Despite the widespread use of anti-VEGF therapy, between 20 and 67% of nAMD patients develop this sight-threatening condition within 2 to 7 years, making fibrosis one of the main reasons responsible for anti-VEGF resistance and irreversible visual loss. Unlike the quiescent scar of a healed skin wound, subretinal fibrosis is a dynamic, vascularised lesion characterised by persistent and active inflammation, a process aptly termed "hot fibrosis". The molecular mechanisms that drive the conversion of neovascularisation into fibrovascular membrane remain poorly defined. This review summarises the clinical features of macular fibrosis in nAMD. It will then detail the pathological insights gained from advanced clinical high-resolution imaging and post-mortem histopathological investigations. We will also explore how advances in our understanding of the pathogenesis of macular fibrosis, as revealed by preclinical models, are uncovering novel therapeutic targets. Promising approaches include dual-targeting agents (e.g., inhibiting VEGF and Ang-2 or complement pathways), as well as repurposing FDA-approved anti-fibrotics, such as pirfenidone or nintedanib, for ocular delivery. The repurposing of drugs with established safety profiles, reformulated for local intraocular use, offers a particularly resource-efficient pathway.
科研通智能强力驱动
Strongly Powered by AbleSci AI